Earlier this month, a Texas judge issued a contentious decision about a drug named Mifepristone, widely used as an abortion pill and a medication to aid treatment of people who suffer miscarriages. U.S. District Judge Matthew Kacsmaryk, a Trump-appointee with documented anti-abortion views, ruled to suspend use of the drug across the entire country, saying that the Food and Drug Administration didn't properly vet the drug when it was cleared for market over twenty years ago. The FDA has spent quite a bit of time in the national limelight the past few years, largely due to the pandemic. But despite its occupation of headlines, the FDA’s history–and at times contentious relationship with the government that created it–aren’t always as widely covered. This week, Brooke sits down with Daniel Carpenter, the Allie S. Freed Professor of Government at Harvard University and author of the book, “Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA,” to talk about the agency's origins and complicated task in the face of our modern political arena. On the Media is supported by listeners like you. Support OTM by donating today (https://pledge.wnyc.org/support/otm). Follow our show on Instagram, Twitter and Facebook @onthemedia, and share your thoughts with us by emailing [email protected].

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.